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The imprinted insulin-like growth factor 2 (IGF2) gene is expressed predominantly from the paternal allele.
Loss of imprinting (LOI) associated with hypomethylation at the promoter proximal sequence (DMR0) of
the IGF2 gene was proposed as a predisposing constitutive risk biomarker for colorectal cancer. We used
pyrosequencing to assess whether IGF2 DMR0 methylation is either present constitutively prior to cancer
or whether it is acquired tissue-speciﬁcally after the onset of cancer. DNA samples from tumour tissues
and matched non-tumour tissues from 22 breast and 42 colorectal cancer patients as well as peripheral
blood samples obtained from colorectal cancer patients [SEARCH (n5case 192, controls 96)], breast
cancer patients [ABC (n5case 364, controls 96)] and the European Prospective Investigation of Cancer
[EPIC-Norfolk (n5breast 228, colorectal 225, controls 895)] were analysed. The EPIC samples were collected
2–5 years prior to diagnosis of breast or colorectal cancer. IGF2 DMR0 methylation levels in tumours were
lower than matched non-tumour tissue. Hypomethylation of DMR0 was detected in breast (33%) and colorec-
tal (80%) tumour tissues with a higher frequency than LOI indicating that methylation levels are a better indi-
cator of cancer than LOI. In the EPIC population, the prevalence of IGF2 DMR0 hypomethylation was 9.5% and
this correlated with increased age not cancer risk. Thus, IGF2 DMR0 hypomethylation occurs as an acquired
tissue-speciﬁc somatic event rather than a constitutive innate epimutation. These results indicate that IGF2
DMR0 hypomethylation has diagnostic potential for colon cancer rather than value as a surrogate biomarker
for constitutive LOI.
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The insulin-like growth factor 2 (IGF2) gene is expressed
predominantly from the paternal allele and is located within
a cluster of imprinted genes on chromosome 11p15 (1). Loss
of IGF2 imprinting (LOI) manifested by biallelic expression
of IGF2 has been observed in 30–70% of patients with
adult onset cancers such as breast (2), hepatocellular carci-
noma (3), ovarian tumours (4,5), bladder cancer (6) and color-
ectal cancer (7–15). Additionally, IGF2 expression is
up-regulated in many cancers including uterine leiomyomas
(16), colon cancer (17), adrenal cortical tumours (18) and
Wilms tumours (19). Biallelic IGF2 expression is also part
of the aetiology of Beckwith Wiedemann Syndrome (BWS),
which is characterized by foetal overgrowth and a propensity
to develop embryonic and childhood cancers such as rhabdo-
myosarcoma and Wilms tumours (20–22).
Imprinted genes are associated with CpG rich regions that
have allele-speciﬁc DNA methylation known as differentially
methylated regions (DMRs). At the IGF2-H19 locus, these
DMRs have been well characterized in both humans and
mice (23–27). Reciprocal imprinting of IGF2 and H19 is
regulated by a conserved DMR located 2–5 kb upstream of
H19 that acts as a CTCF mediated insulator that controls
access of the IGF2 and H19 promoters to downstream enhan-
cers (28–31). In mice, the H19 DMR acts as an imprinting
control region that acquires methylation in the male germ
cells and subsequently inﬂuences the methylation of the Igf2
DMRs in cis after fertilization (25,32). The H19 DMR and
Igf2 DMRs have been shown in mice to physically interact
in an allele-speciﬁc manner to form higher order chromatin
loops that maintain or preclude Igf2 promoter–enhancer inter-
actions (33,34). In humans, the IGF2 gene has a DMR corre-
sponding to the mouse Igf2 DMR0 which is methylated on the
silent maternal allele and is placenta speciﬁc (24,35). Unlike
mice, the human DMR0 is not placenta speciﬁc (26) and is
methylated on the paternal allele in all tissues (36). The
DMR0 has been shown to contain promoter activity (26),
but its function in the higher order chromatin looping structure
has not yet been elucidated. Biallelic IGF2 expression follows
gain of methylation on the maternal allele at the H19 and IGF2
DMRs in a subset of BWS patients (20,36). Although it has
widely been assumed that cancers with LOI will have the
same methylation epigenotypes as BWS, we have previously
shown that the methylation patterns associated with constitu-
tive LOI at the IGF2 and H19 genes in BWS patients are
not identical to the tumour-associated LOI in Wilms patients
(36). Other studies have shown that the H19 insulator is not
invariably hypermethylated together with LOI in colorectal
cancer (15). Loss of methylation at the IGF2 DMR0 has
been reported to be associated with IGF2 LOI in cancer
studies including Wilms tumour (36,37), esophageal cancer
(38) and colorectal cancer (15).
Constitutive IGF2 LOI predisposes to Wilms tumour and
possibly colorectal cancer (14). LOI associated with IGF2
DMR0 hypomethylation was reported in peripheral blood at
a signiﬁcantly higher frequency in patients with a history of
colorectal cancer than patients without (14,15). Since IGF2
DMR0 is normally methylated on the expressed paternal
allele, it is unlikely that its demethylation directly leads to
reactivation of the maternal allele. Moreover, IGF2 DMR0
hypomethylation has now been reported in osteosarcomas
(39), bladder- (6) and ovarian cancer (5) without an associ-
ation with LOI. Thus, IGF2 DMR0 hypomethylation in
cancer is likely to be indicative of changes in IGF2 transcrip-
tion from the active allele independent of the imprinting status.
Therefore, IGF2 DMR0 methylation levels may be useful
indicators of cancer and constitutive IGF2 DMR0 methylation
levels could be predictive of cancer risk. In this study, we
measured the prevalence of IGF2 DMR0 hypomethylation in
tumour tissue samples from colorectal cancer and breast
cancer patients and compared this to IGF2 imprinting status
in these tissues. We also investigated whether IGF2 hypo-
methylation is present in peripheral blood prior to the onset
of breast or colorectal cancer by screening a series of
samples selected from the European Prospective Investigation
of Cancer (EPIC-Norfolk) (40) cohort.
Our results indicate that IGF2 DMR0 hypomethylation is
highly prevalent in cancer and detected more frequently than
LOI. Hypomethylation is not present constitutively in peri-
pheral blood prior to cancer suggesting that it is an acquired
somatic epimutation and therefore a useful indicator of
breast and colorectal cancer.
RESULTS
Validation of methylation pyrosequencing assay
Pyrosequencing is a real-time sequencing methodology that
has been successfully used to quantify bisulphite modiﬁed
cytosine to thymine changes (41,42). We designed and vali-
dated a pyrosequencing assay for IGF2 methylation within
the DMR0 region (Fig. 1A) which included six CpGs, three
of which were previously reported to be hypomethylated
(CpG15–17) in peripheral blood samples from colorectal
patients with LOI at IGF2 (15). The pyrosequencing assay is
linear (Fig. 1B) and IGF2 methylation levels between 7 and
35% consistent with hypomethylation were obtained when
genomic DNA from pooled lymphocyte samples was diluted
2- and 4-fold with unmethylated DNA. Methylation levels
between 42 and 50% consistent with normal monoallelic
methylation were obtained when genomic DNA was undiluted
with unmethylated DNA. Based on this result, we predict that
if DMR0 methylation levels of 35% and less were obtained in
a heterogeneous cell population such as a tumour sample, this
would be indicative of 30% or more cells having no DMR0
methylation on the paternal IGF2 allele.
Our assay reliably measures methylation levels in a popu-
lation of PCR products representative of both parental
alleles. This was veriﬁed by comparing methylation levels of
individual alleles to total methylation levels in a panel of 10
peripheral blood DNA samples from healthy individuals that
were informative for a G/A polymorphism (Fig. 1C). IGF2
DMR0 methylation levels were 0–20% at unmethylated
alleles and between 80 and 100% at methylated alleles. The
average methylation between G and A-alleles in each
sample was between 35 and 55% consistent with the total
methylation levels obtained with our standard pyrosequencing
assay. Conventional bisulphite sequencing of cloned PCR pro-
ducts showed that the methylation levels of CpGs analysed
2634 Human Molecular Genetics, 2008, Vol. 17, No. 17were concordant and that amplicons separated into methylated
and unmethylated alleles, with the exception of CpG13
(Fig. 1D). Thus, our assay measuring total methylation
levels in a population of PCR products could reliably dis-
tinguish between normal differentially imprinted methylation
(45–50%) and hypomethylation ( 35%).
Baseline methylation levels for IGF2 DMR0
Baseline IGF2 methylation levels were established for the
DMR0 region in 233 non-cancerous peripheral blood, 189
term placentae, 10 normal colon and 10 normal breast tissue
samples. Figure 2A shows that methylation at individual
CpGs in this region were interrelated with CpGs 14 and 17
having the lowest methylation, while CpG13 was higher in
all tissues. Allele-speciﬁc methylation assays described
above indicated that CpG13 was not monoallelically methyl-
ated in blood. This CpG13 lies within a homopolymeric
sequence tract and was refractory to pyrosequencing. We
therefore excluded CpG13 when calculating average methyl-
ation levels for the IGF2 DMR0 in subsequent population
studies. Baseline methylation levels (methylation average of
CpG12, 14–17) for peripheral blood, colon, term placentae and
breast tissue samples were 45, 48, 45 and 50%, respectively.
Our sample sizes for peripheral blood and placentae were
large enough to establish that average methylation at the
IGF2 DMR0 for these sample sets followed a unimodal
negatively skewed frequency distribution with median
Figure 1. Pyrosequencing assay to detect methylation levels at the IGF2 DMR0. (A) The human IGF2 gene showing positions of DMRs relative to exons and
active promoters on the paternal allele. IGF2 promoters access enhancers downstream of H19 (ovals) when the CTCF binding site within the H19 DMR is
methylated. IGF2 and H19 genes are 100 kb apart. The DMR0 region within the IGF2 has been reported to be hypomethylated in colorectal cancer. The
expanded region shows the 26 CpGs within this region and the CpGs that we assayed for methylation by pyrosequencing. Our assay encompassed a 255 bp
region, which includes six CpGs (CpG12–17 NCBI36 2125904–2126160). CpG15–17 were previously reported to be hypomethylated in colorectal patients
with LOI at IGF2 (15). Arrows indicate position and direction of biotinylated, pyrosequencing (PSQ) and sequencing primers. Circles indicate individual
CpGs on expanded DMR0. (B) Linearity of pyrosequencing assay: unmethylated template was obtained by PCR ampliﬁcation of target DMR0 sequence
prior to bisulphite conversion. After bisulphite conversion, the unmethylated template was serially diluted with PCR product obtained from bisulphite converted
genomic DNA. At 100% genomic DNA, we have close to 50% methylation which is as expected for normal imprinting. (C) Pyrosequencing proﬁles for allele-
speciﬁc methylation compared to total methylation. Total methylation levels reliably reﬂected the average of the two alleles. (D) Methylation diagrams for 12
cloned PCR products from bisulphite-treated DNA showing that alleles separate into methylated and unmethylated alleles and that methylation at CpG13 is not
allele-speciﬁc. Filled and open circles denote methylated and unmethylated CpGs.
Human Molecular Genetics, 2008, Vol. 17, No. 17 2635methylation levels 43.8% (IQR 41.2, 46.9) in blood and 45.2%
(IQR 42.8, 46.7) in placentae. The skewness was 21.126 and
22.445 for blood and placentae samples, respectively
(D0 Agostino–Pearson normality test, P , 0.0001) and this
was due to a dominant left tail demonstrating individuals
with methylation levels less than 35% (Fig. 2B). It is also
noteworthy that methylation levels did not exceed 60% and
that less than 1% of individuals had methylation levels
above 55% indicating that hypermethylation of IGF2 DMR0
is rare in peripheral blood and placenta samples of normal
individuals. It has been suggested that 10% of normal individ-
uals are constitutively hypomethylated for the IGF2 DMR0
(14). In our assay, 7.5% of peripheral blood and 4% of placen-
tal samples had less than 35% methylation. We therefore set
35% methylation as a cut-off for of hypomethylation.
We examined IGF2 imprinted status in three placental RNA
samples that were informative for the Apa1 polymorphism and
which were hypomethylated at IGF2 DMR0, these were all
mono allelic indicating that in placenta constitutive hypo-
methylation of DMR0 does not correlate with LOI.
RNA was available from 70 of the peripheral blood samples,
and 30 of these were informative for the Apa1 polymorphism,
IGF2 expression levels were very low and we did not detect
LOI in any of the samples including 1 sample that had hypo-
methylation of IGF2 DMR0. The results conﬁrm that in
normal tissue, IGF2 hypomethylation is not associated
with LOI.
IGF2 methylation levels in colorectal cancer
We examined tumour tissue and matching normal control
tissue from 42 colorectal cancer patients. Median methylation
at the IGF2 DMR0 in tumours were 28.6% (IQR 22.0; 32.3)
compared to adjacent normal tissue 45.3% (IQR 38.9; 47.1).
Methylation levels  35% were found in 34 (80%) of
tumours compared to 4 (10%) adjacent normal colon tissue
samples (Fig. 3A). IGF2 DMR0 methylation was reduced in
tumours compared to paired normal tissue in 38 (90%) patients
(Fig. 3B). Methylation levels for individual CpGs within the
DMR0 were interrelated similar to controls and are as
shown in Supplementary Material, Figure S1.
IGF2 methylation levels relative to genomic imprinting
status in colorectal cancer
Previous studies have shown that IGF2 DMR0 hypomethyla-
tion is associated with LOI in colorectal cancer (15) and
Wilms tumour (36,37). Fourteen colorectal cancer patients
were heterozygous for the Apa1 polymorphism in exon 9 of
IGF2 enabling us to examine the RNA for LOI. Nine (64%)
of our informative cases were biallelic for IGF2 expression
in their tumours with median methylation levels of 23.9%
(range 11.6–39.0) compared to ﬁve tumours which showed
normal imprinting with median methylation level 32.9%
(range 19.4–47.1 Wilcoxon Rank Sum tests W ¼ 10,
P ¼ 0.26) (Fig. 3C). If DMR0 methylation levels are indica-
tive of LOI, then we would expect most of our informative
tumour samples to have LOI, since the methylation levels in
these tumours were low. Instead we found normal monoallelic
IGF2 expression in four tumours with low methylation levels
(range 19.4–32.9%). LOI was also detected in three (20%) of
the normal colon tissue biopsies. In these samples, the
methylation levels were 38.8, 40.0 and 36.6% which was sig-
niﬁcantly lower than adjacent normal tissue without LOI with
median methylation levels of 47.3% (range 32.4–63.3, n ¼ 11
Wilcoxon Rank Sum test W ¼ 3, P ¼ 0.038) (Fig. 3C). The
positive predictive value (PPV) was calculated using a cut
off of  35 being positive and .35 being negative. This
shows the probability that a patient with a methylation value
 35% will have LOI in their tumours is PPV 66.7% (95%
CI: 29.9%, 92.5%), while in non-tumour tissue the probability
that a patient with a methylation value  35% will have loss of
imprinting (LOI) is 100.0% [95% CI: 2.5%, 100.0%]. The
95% conﬁdence intervals (CI) are Pearson–Clopper exact con-
ﬁdence intervals. So while all cases with LOI had hypomethy-
lation at IGF2 DMR0, the inverse is not true and DMR0
hypomethylation is not invariably associated with LOI in
tumours.
Figure 2. Distribution of average CpG methylation across IGF2 DMR0 and
population frequency of methylation in a cohort of peripheral blood and pla-
centae. (A) Graph showing average methylation levels of each CpG across the
IGF2 DMR0 in peripheral blood, normal colon, normal breast and term pla-
centae samples. (B) Cumulative frequency distribution of average methylation
levels for CpG12, 14–17 in the IGF2 DMR0 in placentae and peripheral
blood. At the 90% percentile average methylation levels for the DMR0 was
48%; at the 10% percentile, the average methylation level was less than 35%.
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Methylation levels at IGF2 DMR0 were examined in 22 breast
tumours and matched control tissues from the same patients.
Median methylation levels in tumours were 35.5% (IQR
29.2; 43.5), compared to 48.9% (IQR 45.5; 52.1) in the
normal tissue as shown in Figure 3D. Over half of the
tumours (n ¼ 13) had methylation levels that were lower
than their corresponding normal tissue samples (Fig. 3E),
but only seven cases (33.3%) had less than 35% methylation.
Nine of the breast cancer cases were informative for the Apa1
polymorphism and showed normal imprinting, despite two of
these cases having hypomethylation at IGF2. Loss of hetero-
zygosity for IGF2 was excluded in these patients. These
results reﬂect that in breast tumours hypomethylation is less
prevalent than in colorectal tumours and in our small sample
of informative cases reduced IGF2 methylation levels did
not associate with LOI. Methylation levels for individual
CpGs within the DMR0 were interrelated similar to controls
and are as shown in Supplementary Material, Figure S1.
Hypomethylation and cancer in a prospective
population study
Since hypomethylation of IGF2 DMR0 is a feature of colorec-
tal, and to a lesser extent, breast cancer, we set out to deter-
mine whether IGF2 DMR0 hypomethylation is present
constitutively prior to the onset of these cancers in 1348
DNA samples from a subgroup of The European Prospective
Investigation of Cancer (EPIC-Norfolk) cohort of peripheral
blood samples. Within this population, we had two nested
populations consisting of individuals who went on to
develop breast (n ¼ 228) or colorectal cancer (n ¼ 225) 2–5
years after contributing to the EPIC study. The sample set
was selected so that the control and cancer samples were
age matched (range 60–80 years) as shown in Table 1. The
methylation levels in our EPIC population indicated that
9.5% had hypomethylation ( 35% threshold). These
samples veriﬁed by clonal analysis with conventional bisul-
phite sequencing to have no methylation on either allele
(results not shown). Within the EPIC control population,
Figure 3. IGF2 DMR0 methylation levels in colorectal and breast cancers compared to normal tissue from same patients and non-cancer patients: prevalence of
hypomethylation in breast and colorectal cancer tumours. (A) DMR0 methylation levels in DNA from colon tissue from patients with no cancer (Colon NC), and
colorectal cancer patients’ tumour tissue (CRC-T) and matched control biopsies of non-tumour tissues (CRC-NT). Tumours have signiﬁcantly lower methylation
than non-tumour tissue from same patients and this is lower than in colons from patients without cancer. (B) Line plots showing individual data comparisons
between colorectal tumour (CRC-T) and matched control biopsies of non-tumour tissues (CRC NT). (C) LOI relative to IGF2 DMR0 methylation in colorectal
cancer tissue: colorectal cancer patients with LOI have lower methylation in colon tissue than patients without LOI. Colorectal tumours (CRC-T) have lower
methylation than non-tumour tissues (CRC NT) regardless of LOI. (D) DMR0 methylation levels in DNA from breast tissue from individuals with no cancer
(Breast NC) and breast cancer patients’ tumours (BC-T) and matched control biopsies of non-tumour tissue (BC-NT). Breast cancer tumour tissues have sig-
niﬁcantly lower methylation levels than non-tumour tissue. Non-tumour tissue from breast cancer patients has a wider variation of methylation levels than
tissue from non-cancer patients, but median levels are not signiﬁcantly different. (E) Line plots showing individual data comparisons between breast tumour
(BC-T) and matched control biopsies of non-tumour tissues (BC NT). (Box and whisker plots represent Median and IQR with max and min values.
P-values calculated by Wilcoxon Rank sum test.)
Human Molecular Genetics, 2008, Vol. 17, No. 17 2637IGF2 DMR0 methylation levels decreased with age suggesting
that loss of methylation is an acquired epigenetic change
(Table 2 and Supplementary Material, Fig. S2). In addition
to age, gender also had a signiﬁcant inﬂuence on methylation
levels. Females were less frequently hypomethylated than
males at IGF2 (Table 2). Importantly, no evidence for an
association was found with individuals with methylation
levels below the 35% threshold for either colorectal or
breast cancer (Table 3). Since the underlying population con-
tained a substantial proportion of cancer cases (228 breast and
225 colorectal), it is unlikely that methylation levels at the
IGF2 DMR0 could distinguish individuals who are predis-
posed to cancer. These data indicate that IGF2 DMR0
hypomethylation is acquired in peripheral blood with age,
but does not predict future risk for breast or colorectal cancer.
Frequency of IGF2 DMR0 hypomethylation in peripheral
blood in a cross-sectional population study
Our data from the EPIC cohort indicated that constitutive
hypomethylation at IGF2 DMR0 shows no evidence of pre-
dicting colorectal or breast cancer so we wanted to know to
what extent hypomethylation is acquired during carcinogen-
esis. Previously published reports have described LOI in per-
ipheral blood of colorectal cancer patients in a
cross-sectional study, so we tested whether the incidence of
IGF2 hypomethylation in peripheral blood would be higher
in patients already diagnosed with colorectal or breast
cancer. We, therefore, analysed further cohorts of peripheral
blood samples from patients diagnosed with colorectal
cancer (n ¼ 192) and 96 control samples [SEARCH sample
set (43)] as well as breast cancer (n ¼ 364) samples plus 84
controls [ABC cohort (44)] (Tables 1 and 4). We found that
the frequency of individuals with hypomethylation (methyl-
ation levels  35%) in the colorectal cancer patients was 9%
which was similar to the EPIC population, but higher than a
control population where the incidence was 6.4% (Table 5).
These small differences were not statistically signiﬁcant and
can be explained by the differences in age of the case and
control population. There was no evidence of a difference
between breast cancer and control samples at threshold
levels less than 35% (Table 5).
DISCUSSION
IGF2 DMR0 hypomethylation has been suggested as a sur-
rogate biomarker for LOI with the potential to predict inherent
predisposition to cancer. DNA methylation studies are more
robust and quantitative compared to RNA expression studies
and therefore amenable to high throughput analysis or use as
clinical biomarkers. In this study, we have evaluated IGF2
methylation levels at the DMR0 region in DNA from breast
and colorectal cancer tissue biopsies, as well as in large
Table 1. Baseline characteristics of cancer cases and controls by cancer site
Cases Controls
EPIC-Norfolk, 1993–2003
(prospective)
Breast cancer, number 228 460
Age (years) 60.5 (59.4–61.7) 60.3 (59.5–61.1)
Smoking (pack years) 16.3 (0.1–62.5) 16.87 (0.05–59.5)
Body mass index (kg/m
2) 26.6 (26.2227.0) 26.75 (26.2–27.3)
Family history of cancer (%) 45 (19.7%) 75 (16.3%)
Colorectal cancer, number 225 435
Age (years) 66.1 (65.1–67.1) 66.1 (65.3–66.8)
Men (%) 56.4 55.2
Smoking (pack years) 22.3 (0.1–93) 22.0 (0.4–126)
Body mass index (kg/m
2) 27.1 (26.6–27.7) 26.3 (25.9–26.6)
Family history of cancer (%) 34 (15.1%) 69 (15.9%)
SEARCH (cross-sectional) colorectal
cancer, number
192 96
Age (years) 65.9 (65.1–66.8) 43.2 (42–44.4)
Men (%) 57.3 29.5
Smoking (pack years) 24.8 (21.4–28.2) 13.8 (1.3–17.3)
Body mass index (kg/m
2) 26.7 (26.1–27.3) 26.6 (25.1–28.1)
Family history of cancer (%) N/A N/A
ABC (cross-sectional) breast cancer,
number
338 84
Age (years) 52.6 (51.8–53.4) 43.2 (42–44.4)
Body mass index (kg/m
2) 26.6 (26.2–27.1) 26.6 (25.1–28.1)
Smoking (pack years) N/A N/A
Family history of cancer (%) N/A N/A
Data are means and 95% CIs, unless otherwise stated. Numbers vary due
to missing values for BMI. Cancer includes breast or colorectal cancer.
N/A: data not available.
Table 2. Association between loss of methylation at the IGF2 DMR0 locus in
blood DNA and selected study characteristics in controls at baseline, EPIC-
Norfolk, 1993–2003 (cut off 35%)
LOM, n ¼ 83 Non-LOM,
n ¼ 812
P-value
Age (year) 67.0 (65.1–68.8) 62.7 (62.1–63.3) ,0.001
Men (%) 31 (37.3) 209 (25.7) 0.023
Smoking (pack years) 22.5 (17.7–27.2) 19.5 (17.8–21.1) 0.21
Body mass index (kg/m
2) 26.7 (26.0–27.4) 26.4 (26.2–26.7) 0.53
Family history of cancer (%) 13 (15.7%) 131 (16.1%) 0.21
Data are means and 95% CIs, unless otherwise stated. Numbers vary due
to missing values for BMI.
Table 3. Association between loss of methylation at the IGF2 DMR0 locus in
b l o o dD N Aa n dr i s ko ff u t u r eb r e a s ta n dcolorectal cancers, EPIC-Norfolk,
1993–2003 (cut off 35%)
Methylation status Cases (%) Controls (%) Model 1
a
Colorectal cancer 225 435
Non-LOM 195 (86.7) 381 (87.6) 1
LOM 30 (13.3) 54 (12.4) OR ¼ 1.09 95% CI
(0.65–1.82) P ¼ 0.74
Breast cancer 228 460
Non-LOM 213 (93.4) 431 (93.7) 1
LOM 15 (6.6) 29 (6.3) OR ¼ 1.04 95% CI
(0.54–2.0) P ¼ 0.91
All cancers 453 895
Non-LOM 408 (90.1) 812 (90.7) 1
LOM 45 (9.9) 83 (9.3) OR ¼ 1.08 95% CI
(0.72–1.61) P ¼ 0.71
aModel 1: additional adjustment for possible confounders, smoking (pack
years), BMI.
2638 Human Molecular Genetics, 2008, Vol. 17, No. 17cohorts of peripheral blood DNA samples from cross-sectional
and prospective populations using a well validated quantitative
pyrosequencing assay.
We have found that IGF2 DMR0 hypomethylation is more
prevalent than LOI and 36% of our colorectal tumour tissue
samples with hypomethylation were monoallelic for IGF2
expression. Interestingly, the tumours with LOI had lower
methylation levels than those without LOI. Since IGF2 DMR0
ismethylatedonthepaternallyinheritedallele(36),itisunlikely
thatthelossofmethylationatthisregionwouldhaveadirectrole
in reactivation of the silent maternal allele. This is supported by
our ﬁnding that IGF2 DMR0 hypomethylation and LOI are not
tightly linked. However, IGF2 DMR0 hypomethylation was
found in 80% of colorectal and 33% of breast cancer tissues
with most of the colorectal and breast cancer patients having
signiﬁcantly lower methylation in their tumours compared to
adjacent non-tumour tissues. These results suggest that hypo-
methylation at IGF2 DMR0 in tumour tissue should not be
viewed as a surrogate biomarker for LOI but as a frequently
identiﬁable attribute of colorectal cancer.
Our second ﬁnding was that in our prospective studies using
the EPIC population samples only 9.5% of samples had  35%
methylation. Based on previous reports in which IGF2 DMR0
hypomethylation in peripheral blood was found to be associa-
ted with colorectal cancer and the perception that loss of
methylation is likely to be an early event in tumorigenesis,
we expected to ﬁnd a higher incidence of colorectal cancer
and possibly also breast cancer in the 10% percentile pro-
portion of the population with hypomethylation. However,
this was not the case and hypomethylation of IGF2 DMR0
was present with similar incidences in controls and persons
who later went on to develop cancer. This observation
indicates that constitutive hypomethylation of IGF2 is actually
rare and not a predetermining factor for colorectal or breast
cancer.
It has recently been shown that Dnmt3b-mediated methyla-
tion in cancer targets speciﬁc genes rather than being a sto-
chastic random event (45). It is possible that demethylation
is also targeting speciﬁc loci during cancer and that IGF2
DMR0 is one such region. Demethylation in cancer may be
passively mediated by failure to maintain methylation during
replication or active via DNA repair mechanisms (46,47).
Age-related DNA methylation changes at the IGF2/H19
locus have been previously reported (48) and there are also
indications that heritable factors may determine methylation
levels at this locus (49). Within the EPIC sample set we
found a strong correlation with age and hypomethylation
(Table 2). In our study, IGF2 DMR0 methylation decreased
after 60 years of age. Thus, if genetic factors initially pre-
dispose to hypomethylation, environmental or age-related
factors probably augment hypomethylation. We have recently
reported that the methylation proﬁles in congenital growth dis-
orders with IGF2 LOI and Wilms tumour cases with IGF2
LOI are not the same (36). This would suggest that even if
similar epigenetic reprogramming mechanisms operate in the
germ-line and in cancer tissues the IGF2 and H19 DMR
sequences respond differently.
The results of our study in the EPIC samples contradict
reports that show an increased frequency of LOI in peripheral
blood samples of colorectal cancer patients (13–15). The per-
ipheral blood samples in these authors’ studies came from
individuals who were known to have LOI in colon tissue.
The difference in our study is ﬁrstly that our prospective
study utilized blood samples that did not come from the
same patients as our tumour samples. Secondly, we looked
at IGF2 DMR0 methylation levels as an indicator for cancer
predisposition, whereas other studies examined LOI in
mRNA. IGF2 expression is very low in peripheral blood
samples. RNA analysis by nested PCR in peripheral blood
could enrich for a subset of IGF2 expressing cells with LOI
that is beyond the range of detection of quantitative pyro-
sequencing methylation analysis.
Overall, our results show that hypomethylation of IGF2
DMR0 is an acquired cancer-speciﬁc epigenetic event. Hypo-
methylation of IGF2 DMR0 is more frequent than LOI and
may be a consequence of LOI as well as other cancer-speciﬁc
epigenetic-mediated events such as chromosomal and chroma-
tin rearrangements at the locus. It is plausible that the detection
oflowerlevelsofmethylationincancertissuesamplesreﬂectsa
relative sampling effect in tumours with less-differentiated cell
populations. Routine single cell analysis of methylation in situ
is not yet feasible, but if loss of methylation at the DMR0 is a
feature of less differentiated cells, then pyrosequencing assays
for methylation may prove a valuable alternate tool for quanti-
fyinglessdifferentiated cells inheterogeneous tumoursamples.
BecauseIGF2DMR0hypomethylationissohighlyprevalentin
colon tissue from colorectal cancer patients and rarely present
constitutively, it has a value as a diagnostic indicator of color-
ectal cancer and should be added to the modest list of discrimi-
nant methylation markers suitable for cancer screening
(50–53). Currently, there is no national UK screening pro-
gramme aimed at reducing colorectal cancer-related deaths.
The Danish (54) and the Nottingham (55) randomized con-
trolled trials and the colorectal screening pilot study (56) have
shown the efﬁcacy of screening with faecal-occult-blood test
(FOBT) in reducing colorectal cancer-related mortality. The
PPV of FOBT ranges from 9 to 17% with a sensitivity of
52% (56). Such low sensitivity and PPV result in a large
number of unnecessary colonoscopies and highlight the need
for a test with better predictive value. Our IGF2 DMR0
Table 4. Association between loss of methylation at the IGF2 DMR0 locus in
blood DNA and selected study characteristics in SEARCH and ABC dataset
LOM Non-LOM P-value
SEARCH, n 23 259
Age (year) 60.3 (54.9–65.6) 58.1 (56.7–59.7) 0.44
Men (%) 47.8 47.5 0.98
Smoking (pack years) 22.7 (16.3–29.2) 21.9 (18.9–24.9) 0.87
Body mass index (kg/m
2) 25.6 (23.6–27.5) 26.8 (26.1–27.5) 0.32
Family history of cancer
(%)
N/A N/A N/A
ABC, n 25 397
Age (year) 55.42 (52.7–58.1) 52.44 (51.6–53.3) 0.29
Smoking (pack years) N/A N/A
Body mass index (kg/m
2) 26.6 (24.6–27.6) 26.8 (26.0–27.5) 0.33
Family history of cancer
(%)
N/A N/A
Data are means and 95% CIs, unless otherwise stated. Numbers vary due
to missing values for methylation. N/A, data not available.
Human Molecular Genetics, 2008, Vol. 17, No. 17 2639hypomethylation assay is robust and requires only 100 ng of
DNA which makes it suitable as a screening test to complement
FOBT. While the clinical application of these results with
regard to diagnostic value is clear, detailed analyses of hypo-
methylation and IGF2 expression levels in subgroups of color-
ectal tumours, and normal tissue at different stages of disease
are still required in order to evaluate the prognostic value of
IGF2 hypomethylation.
MATERIALS AND METHODS
Patient and population samples
Colorectal and breast tumour samples. DNA and RNA from
Colorectal tumour samples and adjacent controls were
extracted from tissue obtained from the Addenbrooke’s hospi-
tal (NIHR Cambridge Biomedical Research Centre, LREC 06/
Q0108/307).
Colorectal tissue was collected from surgically resected
colectomy specimens where normal tissue, ‘near’ and
‘further away’ from the tumour as well as carcinoma tissue
samples were available. Sections from tissue immediately
adjacent to the analysed samples were examined to conﬁrm
their histological nature.
DNA and RNA from breast tumour samples and adjacent
controls were extracted from tissue that had been collected
during surgery from patients treated at Colchester General
Hospital (Essex, UK), with written consent taken before
surgery (OREC ref MH363). The samples were immediately
frozen and stored at 2808C. Breast cancers were invasive
ductal carcinomas (n ¼ 12); invasive adenocarcinomas
(n ¼ 6); tumours with mixed phenotypes (n ¼ 2); DCIS
(n ¼ 1) and mucinous carcinomas (n ¼ 1).
Placenta samples. Placental tissues were collected from term
pregnancies at Queen Charlotte’s and Chelsea Hospital,
London under the guidance of Hammersmith and Queen Char-
lotte’s and Chelsea Hospital Trust Research Ethics Committee
(ref 2001/6029). From each placenta, ﬁve 1 cm
3 biopsies were
sectioned from the foetal side and washed three times in
1xPBS to remove maternal blood, and DNA extraction was
performed as previously described (26).
Peripheral blood samples. DNA from peripheral blood
samples was obtained from the following cohorts
EPIC—Norfolk population (40); SEARCH population (43);
Breast Cancer Consortium (ABC) (44). All cancers in these
cohorts were invasive, i.e. no polyps or DCIS were included.
Information on grade and stage of cancers was not made
available.
The cases and controls were randomly allocated and
methylation assays were done blind to case–control status.
The nested study design utilizing the EPIC samples uniquely
capitalises on the fact that DNA was extracted from indivi-
duals who were healthy and subsequently went on to develop
disease. This approach provides an exceptional opportunity
to examine whether the loss of methylation at IGF2 DMR0
occurs prior to disease onset. The cases within the SEARCH
and Breast Cancer Consortium populations had been diag-
nosed with colorectal and breast cancer at the time of blood
collection. Number of samples required for statistical power
of 80% with an alpha of 0.01 were calculated to be 200–
250 cases and 400–500 based on an assumption that the
true relative risk is two, which would be consistent with a sim-
plistic exposure-risk models (in this case, normal methylation
exposure to hypomethylated exposure), and that based on
earlier literature (57,58), 10% of controls were expected to
have hypomethylation.
Analysis of imprinting status
IGF2 imprinting status was determined by assaying for Apa1
polymorphism (rs680) within the IGF2 exon 9 by restriction
digestion or sequencing of PCR products obtained as
described previously (14). We called LOI when we could
clearly see two visible bands on a gel which was at least in
a 1:4 ratio. Sequence traces were called biallelic when two
peaks above background could be discerned.
Pyrosequencing assay
Our pyrosequencing assay for IGF2 DMR0 region (Fig. 1)
is as described previously (36) and included six CpGs,
three of which were previously reported to be hypo-
methylated in colorectal patients with LOI at IGF2 (15).
For high through-put analysis, the following controls were
included on each 96 well plate: DNA from a cell line
SUM159 which has 0–20% methylation at IGF2 DMR0
as well as commercially obtained pooled peripheral blood
Table 5. Association between loss of methylation at the IGF2 DMR0 locus in blood DNA and risk of cancers in SEARCH and ABC datasets (cut off 35%)
Methylation status Cases (%) Controls (%) Model 1
a Model 2
b
SEARCH
Colorectal cancer 188 94
Non-LOM 171 (91.0%) 88 (93.6%) 1 1
LOM 17 (9.0%) 6 (6.4%) 1.33 (0.08–22.7) P ¼ 0.8 1.63 (0.06–42.5) P ¼ 0.77
ABC
Breast cancer 338 84
Non-LOM 319 (94.4%) 78 (92.9%) 1 1
LOM 19 (5.6%) 6 (7.1%) 0.93 (0.78–1.187) P ¼ 0.65 0.65 (0.296–2.005) P ¼ 0.77
CI, conﬁdence interval.
aModel 1: Adjusted for age, and sex.
bModel 2: Additional adjustment for possible confounders, smoking (pack years), BMI.
2640 Human Molecular Genetics, 2008, Vol. 17, No. 17leucocyte DNA (BD Biosciences, Clonetech range) which
had methylation levels of 42–43%. These samples
enabled us to check our inter-assay variation. Using a
minimum of 100 ng of DNA as template for bisulphite con-
version eliminated experimental error due to allele drop-out
and the inter- and intra-assay variability was 5 and 2%,
respectively. Linearity of the assay was checked by
adding unmethylated template sequences (obtained by
PCR ampliﬁcation of target sequence, and then bisulphite
converting the PCR products) in varying concentrations to
bisulphite converted genomic DNA.
The methylation quantiﬁcation was analysed by PSQ HS
96A SNP and Pyro Q-CpG Software (Biotage, Uppsala,
Sweden) and other than excluding samples that did not meet
quality control checks the data was not normalized.
In the EPIC cohort, we veriﬁed allele-speciﬁc loss of
methylation by conventional bisulphite sequencing of cloned
PCR products in sample of 12 hypomethylated cases and simi-
larly conﬁrmed allele-speciﬁc methylation in a further ﬁve
random cases from the cohort.
Statistical analysis
GraphPad Prism software was used to determine Medians and
IQR for tumour and control samples and for D’ Agostino and
Pearson omnibus normality tests which returned skewness and
Kurtosis values on methylation proﬁles of peripheral blood
and placenta samples. Free software from R Development
Core Team http://www.R-project.org was used for Wilcoxon
Rank Sum test to determine whether there were differences
in methylation levels in tumours and adjacent non-tumour
tissues, as well as in cases with and without LOI. PPVs
were calculated in Microsoft Excel using Pearson Clopper
Exact Conﬁdence intervals because of the small sample
size (59).
For larger data sets such as the EPIC, ABC and SEARCH
cohorts, baseline characteristics of cancer cases and con-
trols by cancer site were calculated using means and 95%
conﬁdence intervals. Loss of methylation (LOM) was
deﬁned as level of methylation  35% and non loss of
methylation (non-LOM) is equivalent to a methylation
status .35%. Mean age, smoking pack per year and BMI
(continuous variables) were analysed in LOM and
non-LOM groups using the t test statistic. We used a x
2
test to compare proportions such as family history of
cancer and sex ratio with LOM and non-LOM. Because
this study is a match case and control study, association
between case/control status and LOM was examined using
conditional logistic regression (ﬁxed effect). At ﬁrst, we
tested the association for breast and colorectal cancer sep-
arately; we then pooled both cancers and tested the associ-
ation. Conditional logistic regression models were adjusted
for BMI, number of packet smocked per year and family
history of cancer.
P-values less than 0.05 were considered to be statistically
signiﬁcant. We used the STATA statistical package, version
8.2 (Stats Corp., College Station, TX, USA) for all analyses.
All P-values were two-sided.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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